Navigation Links
Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
Date:1/19/2009

anies in Wallonia at the cutting-edge of technology by providing financing solutions in a difficult financial environment."

About Cardio3 BioSciences

Cardio3 BioSciences is a leading Belgian biotechnology company specialising in stem cell-based therapies for the treatment of cardiovascular disease. The Company's lead product, C-Cure is a highly innovative approach to the treatment of heart failure, one of the world's most pressing unmet medical needs. Based on a strategy developed by Cardio3 BioSciences' founders and leveraging technology from Mayo Clinic, C-Cure allows the differentiation of a patient's own cells into 'cardiopoeitic' cells which grow into new heart cells and repair heart muscle. An international clinical trial of C-Cure sponsored by Cardio3 BioSciences is expected to begin in early 2009.

The Cardio3 BioSciences team has extensive experience in developing and commercialising new pharmaceutical products and medical technologies and the Company's strategy is to drive the clinical development of C-Cure and to market the product itself in major territories.

Cardio3 BioSciences was founded in July 2007 and is based in Mont-Saint-Guibert in the Walloon region of Belgium.

About C-Cure(R)

C-Cure is a second generation cell therapy for the treatment of heart failure that involves taking a patient's own stem cells from bone marrow and through a proprietary culturing technology generating differentiated 'cardiopoeitic' cells which can regenerate damaged heart muscle. Unlike previous cell therapies for this indication, C-Cure is designed to produce new autologous heart muscle cells which behave identically to those lost in infarction without carrying the risk of rejection.

C-Cure draws on the unrivalled understanding of the fundamental science of heart cell development within Cardio3 BioSciences and on technology developed at Mayo Clinic, one o
'/>"/>

SOURCE Cardio3 BioSciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today reported financial results for ... Global revenue for the Company,s Urgent ®  PC ... quarterly revenue record, as compared to $3.9 million in ...
(Date:1/22/2015)... WOODBRIDGE, ON , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics ... company with a focus on Omega-3 therapies for cardiovascular disease ... summary of the Company,s accomplishments in 2014 and its outlook ... Dear Fellow Shareholders, We would like ...
(Date:1/22/2015)... 2015  Bio-Techne Corporation (NASDAQ: TECH ) announced ... of the new Simple Plex platform through its Proteins ... the re-branding of the previously acquired CyPlex instrument platform ... a transformative immunoassay technology which integrates an innovatively designed ...
Breaking Medicine Technology:Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
... /PRNewswire-Asia/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: ... patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded ... the earnings conference call for the third quarter of ... be held at 9:00 a.m. ET on Tuesday, May ...
... 2012 First Quarter Total Revenue $856 million, including $66 million ... forma organic growth for the combined company, adjusting for the impact ... 2012 First Quarter GAAP EPS Loss of $0.04; Cash EPS ... was $0.99 , 2012 First Quarter GAAP Cash ...
Cached Medicine Technology:TPI to Host Third Quarter of Fiscal Year 2012 Earnings Conference Call on Tuesday, May 15, 2012 at 9:00 a.m. ET 2Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 2Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 3Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 4Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 5Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 6Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 7Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 8Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 9Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 10Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 11Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 12Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 13Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 14Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 15Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 16
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... 22, 2015 Lower-Auto-Insurance.com has released a new blog ... a car for reducing the costs of an auto insurance ... be able to get lower prices for their vehicle insurance policies. ... role in determining policy costs. Because of this, drivers should ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... the leading cause of blindness for blacks and whites ... is the leading cause of blindness for whites, while ... for blacks. ,More than 50 percent of the ... degeneration. In contrast, more than 60 percent of the ...
... are often disfiguring and leave patients with gaping wounds or deep ... the person's own body to heal the area and improve their ... toddler and then as a teenager and young adult. Decades later, ... the cancer grew back -- this time as a tumor behind ...
... late at night, when hunger strikes may seem a familiar ... people do // not eat enough throughout the day. People ... tend to crave carbs and sweets . ,Studies show ... and angry. When these same people resume normal eating habits, ...
... dairy products may actually make you smaller -- by promoting ... to drink your milk so you can grow bigger, she ... study who consumed more calcium lost more weight. Researchers say ... occurs. However, if the body consumes an insufficient amount of ...
... of the leading causes of blindness in the United States. ... light-sensitive // layer of cells at the back of the ... its incidence can be reduced with aggressive control of blood ... Americans, age 40 or older, suffer from diabetic retinopathy, and ...
... for the treatment of erectile dysfunction, may also help ... hypertension. Chronic pulmonary hypertension causes blood pressure to rise ... death. Researchers say there is little that can be ... for infants with chronic pulmonary hypertension usually involves delivering ...
Cached Medicine News:Health News:Tissue Transfer for Skin Cancer 2
... 2000 is an ... for automated 96-/384-well ... With its ability ... any routine liquid ...
... Multidrop 384 offers lower consumption of ... screening applications. The Multidrop 384 is ... screening and microvolume dispensing into 384- ... outstanding flexibility. It can easily switch ...
RIA kit for the determination of blocking autoantibodies to the acetylcholine receptor (AChR) in serum...
... This personal-sized Thermal Cycler is the ideal instrument ... full range of PCR applications. Get ... price. Save lab space without sacrificing ... Industry-Standard PCR Technology You Can Afford ...
Medicine Products: